Biomea Fusion (BMEA) Cash & Equivalents (2020 - 2026)

Biomea Fusion has reported Cash & Equivalents for 7 years, with the latest figure at $44.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 24.62% year-over-year to $44.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.7 million (up 24.62% YoY) and the FY2025 annual result came in at $55.8 million, down 4.23% from the prior year.
• Cash & Equivalents slipped to $44.7 million in Q1 2026 per BMEA's latest filing, from $55.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $222.9 million in Q2 2023 and troughed at $35.9 million in Q1 2025.
• A 5-year average of $110.7 million and a median of $112.2 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents jumped 728.79% in 2022, then sank 75.32% in 2025.
• Over 5 years, Cash & Equivalents stood at $112.2 million in 2022, then jumped by 57.89% to $177.2 million in 2023, then plunged by 67.12% to $58.3 million in 2024, then fell by 4.23% to $55.8 million in 2025, then dropped by 19.92% to $44.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $44.7 million, $55.8 million, and $47.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.